Ocugen (OCGN) Cash from Financing Activities (2014 - 2026)
Ocugen (OCGN) reported Cash from Financing Activities of $35.0 million for Q1 2026, up 2909.96% on a YoY basis from $1.2 million in Q1 2025, and up 1749100.0% quarter-over-quarter from $2000.0 in Q4 2025.
Ocugen (OCGN) Cash from Financing Activities (2014 - 2026) Analysis & Trends
Ocugen has reported Cash from Financing Activities for 13 years, with the latest figure at $35.0 million in Q1 2026.
- For the quarter ending Q1 2026, Cash from Financing Activities rose 2909.96% year-over-year to $35.0 million; the trailing twelve-month figure through Mar 2026 stood at $53.6 million (down 16.0% YoY), and the FY2025 full-year result was $17.3 million, down 73.28% from the prior year.
- Cash from Financing Activities for Q1 2026 stood at $35.0 million, up from $2000.0 in the prior quarter.
- The five-year high for Cash from Financing Activities was $50.1 million in Q1 2022, with the low at -$1.2 million in Q1 2025.
- Historically, Cash from Financing Activities has averaged $11.6 million across 5 years, with a median of $962000.0 in 2022.
- Annual changes were most pronounced in 2024 — Cash from Financing Activities surged 188475.0% — and 2025, when it sank 758.62%.
- Ocugen's Cash from Financing Activities stood at $8.2 million in 2022, then sank by 99.8% to $16000.0 in 2023, then surged by 188475.0% to $30.2 million in 2024, then sank by 99.99% to $2000.0 in 2025, then jumped by 1749100.0% to $35.0 million in 2026.
- The last three Cash from Financing Activities figures came in at $35.0 million (Q1 2026), $2000.0 (Q4 2025), and $18.5 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 7.00 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -600,000.00 |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 53,000.00 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | -538.80 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 85,464.43 |
| 10 | Ocugen | 411.07 Mn | 411.07 Mn | - | 34.98 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 34.98 Mn |
| Mar 31, 2026 | 34.98 Mn |
| Dec 31, 2025 | 2,000.00 |
| Dec 31, 2025 | 2,000.00 |
| Sep 30, 2025 | 18.51 Mn |
| Sep 30, 2025 | 18.51 Mn |
| Jun 30, 2025 | 61,000.00 |
| Jun 30, 2025 | 61,000.00 |
| Mar 31, 2025 | -1.25 Mn |
| Mar 31, 2025 | -1.25 Mn |
| Dec 31, 2024 | 30.17 Mn |
| Dec 31, 2024 | 30.17 Mn |
| Sep 30, 2024 | 34.79 Mn |
| Sep 30, 2024 | 34.79 Mn |
| Jun 30, 2024 | 45,000.00 |
| Jun 30, 2024 | 45,000.00 |
| Mar 31, 2024 | -145,000.00 |
| Mar 31, 2024 | -145,000.00 |
| Dec 31, 2023 | 16,000.00 |
| Dec 31, 2023 | 16,000.00 |